#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=In the present study , the absorption pattern and pharmacokinetic pattern of free choline from Superba Boost TM krill oil and choline bitartrate were investigated .
3-1	15-17	In	_	_	_	_
3-2	18-21	the	abstract[3]	new[3]	coref	9-25[75_3]
3-3	22-29	present	abstract[3]	new[3]	_	_
3-4	30-35	study	abstract[3]	new[3]	_	_
3-5	36-37	,	_	_	_	_
3-6	38-41	the	abstract[5]	new[5]	_	_
3-7	42-52	absorption	abstract|abstract[5]	new|new[5]	_	_
3-8	53-60	pattern	abstract[5]	new[5]	_	_
3-9	61-64	and	_	_	_	_
3-10	65-80	pharmacokinetic	abstract|abstract[7]	new|new[7]	coref|coref	22-41|22-41
3-11	81-88	pattern	abstract[7]	new[7]	_	_
3-12	89-91	of	abstract[7]	new[7]	_	_
3-13	92-96	free	abstract[7]|substance[8]	new[7]|new[8]	coref	4-6[0_8]
3-14	97-104	choline	abstract[7]|substance[8]	new[7]|new[8]	_	_
3-15	105-109	from	abstract[7]|substance[8]	new[7]|new[8]	_	_
3-16	110-117	Superba	abstract[7]|substance[8]|substance	new[7]|new[8]|new	coref	4-2
3-17	118-123	Boost	abstract[7]|substance[8]	new[7]|new[8]	_	_
3-18	124-126	TM	abstract[7]|substance[8]|object|substance[12]	new[7]|new[8]|new|new[12]	coref|coref|coref|coref	4-2[17_0]|16-22[164_12]|4-2[17_0]|16-22[164_12]
3-19	127-132	krill	abstract[7]|substance[8]|abstract|substance[12]	new[7]|new[8]|new|new[12]	coref	20-1
3-20	133-136	oil	abstract[7]|substance[8]|substance[12]	new[7]|new[8]|new[12]	_	_
3-21	137-140	and	abstract[7]|substance[8]	new[7]|new[8]	_	_
3-22	141-148	choline	abstract[7]|substance[8]|abstract|substance[14]	new[7]|new[8]|new|new[14]	coref|coref|coref|coref	4-26[23_14]|8-5|4-26[23_14]|8-5
3-23	149-159	bitartrate	abstract[7]|substance[8]|substance[14]	new[7]|new[8]|new[14]	_	_
3-24	160-164	were	_	_	_	_
3-25	165-177	investigated	_	_	_	_
3-26	178-179	.	_	_	_	_

#Text=In Superba Boost TM , choline is bound in a lipid-soluble form as phosphatidylcholine , while it is present as a water-soluble salt structure in choline bitartrate .
4-1	180-182	In	_	_	_	_
4-2	183-190	Superba	substance|abstract[16]|object[17]	giv|new[16]|giv[17]	ana|coref|coref|ana|coref|coref|ana|coref|coref	4-17[0_17]|5-12|5-12[29_16]|4-17[0_17]|5-12|5-12[29_16]|4-17[0_17]|5-12|5-12[29_16]
4-3	191-196	Boost	abstract[16]|object[17]	new[16]|giv[17]	_	_
4-4	197-199	TM	object[17]	giv[17]	_	_
4-5	200-201	,	_	_	_	_
4-6	202-209	choline	substance	giv	coref	4-26
4-7	210-212	is	_	_	_	_
4-8	213-218	bound	_	_	_	_
4-9	219-221	in	_	_	_	_
4-10	222-223	a	substance[19]	new[19]	_	_
4-11	224-237	lipid-soluble	substance[19]	new[19]	_	_
4-12	238-242	form	substance[19]	new[19]	_	_
4-13	243-245	as	substance[19]	new[19]	_	_
4-14	246-265	phosphatidylcholine	substance[19]	new[19]	_	_
4-15	266-267	,	_	_	_	_
4-16	268-273	while	_	_	_	_
4-17	274-276	it	object	giv	coref	5-14
4-18	277-279	is	_	_	_	_
4-19	280-287	present	_	_	_	_
4-20	288-290	as	_	_	_	_
4-21	291-292	a	_	_	_	_
4-22	293-306	water-soluble	_	_	_	_
4-23	307-311	salt	substance	new	_	_
4-24	312-321	structure	_	_	_	_
4-25	322-324	in	_	_	_	_
4-26	325-332	choline	substance|substance[23]	giv|giv[23]	coref|coref|coref|coref	5-5|5-16[32_23]|5-5|5-16[32_23]
4-27	333-343	bitartrate	substance[23]	giv[23]	_	_
4-28	344-345	.	_	_	_	_

#Text=Results show that free choline levels in plasma were comparable between Superba Boost TM and choline bitartrate , but peak choline concentrations were reached significantly later upon intake of Superba Boost TM compared to choline bitartrate .
5-1	346-353	Results	abstract	new	_	_
5-2	354-358	show	_	_	_	_
5-3	359-363	that	_	_	_	_
5-4	364-368	free	abstract[26]	new[26]	coref	6-3[41_26]
5-5	369-376	choline	substance|abstract[26]	giv|new[26]	coref	5-16
5-6	377-383	levels	abstract[26]	new[26]	_	_
5-7	384-386	in	abstract[26]	new[26]	_	_
5-8	387-393	plasma	abstract[26]|substance	new[26]|new	coref	12-40
5-9	394-398	were	_	_	_	_
5-10	399-409	comparable	_	_	_	_
5-11	410-417	between	_	_	_	_
5-12	418-425	Superba	organization|abstract[29]	giv|giv[29]	coref|coref|coref|coref	5-30|5-30[37_29]|5-30|5-30[37_29]
5-13	426-431	Boost	abstract[29]	giv[29]	_	_
5-14	432-434	TM	abstract[29]|abstract	giv[29]|giv	coref	5-30[38_0]
5-15	435-438	and	abstract[29]	giv[29]	_	_
5-16	439-446	choline	abstract[29]|substance|substance[32]	giv[29]|giv|giv[32]	coref|coref|coref|coref	5-21|5-35[40_32]|5-21|5-35[40_32]
5-17	447-457	bitartrate	abstract[29]|substance[32]	giv[29]|giv[32]	_	_
5-18	458-459	,	_	_	_	_
5-19	460-463	but	_	_	_	_
5-20	464-468	peak	animal[34]	new[34]	coref	8-3[64_34]
5-21	469-476	choline	substance|animal[34]	giv|new[34]	coref	5-35
5-22	477-491	concentrations	animal[34]	new[34]	_	_
5-23	492-496	were	_	_	_	_
5-24	497-504	reached	_	_	_	_
5-25	505-518	significantly	_	_	_	_
5-26	519-524	later	_	_	_	_
5-27	525-529	upon	_	_	_	_
5-28	530-536	intake	event[35]	new[35]	coref	6-21[48_35]
5-29	537-539	of	event[35]	new[35]	_	_
5-30	540-547	Superba	event[35]|organization|abstract[37]|substance[38]	new[35]|giv|giv[37]|giv[38]	coref|coref|coref|coref|coref|coref|coref|coref|coref	6-23|6-23[50_37]|6-23[51_38]|6-23|6-23[50_37]|6-23[51_38]|6-23|6-23[50_37]|6-23[51_38]
5-31	548-553	Boost	event[35]|abstract[37]|substance[38]	new[35]|giv[37]|giv[38]	_	_
5-32	554-556	TM	event[35]|substance[38]	new[35]|giv[38]	_	_
5-33	557-565	compared	_	_	_	_
5-34	566-568	to	_	_	_	_
5-35	569-576	choline	substance|substance[40]	giv|giv[40]	coref|coref|coref|coref	6-6|6-28[53_40]|6-6|6-28[53_40]
5-36	577-587	bitartrate	substance[40]	giv[40]	_	_
5-37	588-589	.	_	_	_	_

#Text=Moreover , levels of the choline metabolites betaine and DMG were higher , while levels of TMAO were lower upon intake of Superba Boost TM compared to choline bitartrate .
6-1	590-598	Moreover	_	_	_	_
6-2	599-600	,	_	_	_	_
6-3	601-607	levels	abstract[41]	giv[41]	coref	6-15[46_41]
6-4	608-610	of	abstract[41]	giv[41]	_	_
6-5	611-614	the	abstract[41]|substance[43]|substance[44]	giv[41]|new[43]|new[44]	coref|coref	7-13[60_43]|7-13[60_43]
6-6	615-622	choline	abstract[41]|substance|substance[43]|substance[44]	giv[41]|giv|new[43]|new[44]	coref	6-28
6-7	623-634	metabolites	abstract[41]|substance[43]|substance[44]	giv[41]|new[43]|new[44]	_	_
6-8	635-642	betaine	abstract[41]|substance[44]	giv[41]|new[44]	_	_
6-9	643-646	and	abstract[41]	giv[41]	_	_
6-10	647-650	DMG	abstract[41]|person	giv[41]|new	_	_
6-11	651-655	were	_	_	_	_
6-12	656-662	higher	_	_	_	_
6-13	663-664	,	_	_	_	_
6-14	665-670	while	_	_	_	_
6-15	671-677	levels	abstract[46]	giv[46]	_	_
6-16	678-680	of	abstract[46]	giv[46]	_	_
6-17	681-685	TMAO	abstract[46]|abstract	giv[46]|new	_	_
6-18	686-690	were	_	_	_	_
6-19	691-696	lower	_	_	_	_
6-20	697-701	upon	_	_	_	_
6-21	702-708	intake	event[48]	giv[48]	coref	7-4[56_48]
6-22	709-711	of	event[48]	giv[48]	_	_
6-23	712-719	Superba	event[48]|substance|abstract[50]|substance[51]	giv[48]|giv|giv[50]|giv[51]	coref|coref|coref|coref|coref|coref|coref|coref|coref	13-41|13-43[0_51]|14-21[145_50]|13-41|13-43[0_51]|14-21[145_50]|13-41|13-43[0_51]|14-21[145_50]
6-24	720-725	Boost	event[48]|abstract[50]|substance[51]	giv[48]|giv[50]|giv[51]	_	_
6-25	726-728	TM	event[48]|substance[51]	giv[48]|giv[51]	_	_
6-26	729-737	compared	_	_	_	_
6-27	738-740	to	_	_	_	_
6-28	741-748	choline	substance|substance[53]	giv|giv[53]	coref|coref|coref|coref	7-4|13-35[123_53]|7-4|13-35[123_53]
6-29	749-759	bitartrate	substance[53]	giv[53]	_	_
6-30	760-761	.	_	_	_	_

#Text=The dependency between choline intake and circulating levels of free choline and its metabolites is concealed by homeostatic regulations and rapid tissue uptake .
7-1	762-765	The	abstract[54]	new[54]	_	_
7-2	766-776	dependency	abstract[54]	new[54]	_	_
7-3	777-784	between	abstract[54]	new[54]	_	_
7-4	785-792	choline	abstract[54]|substance|event[56]	new[54]|giv|giv[56]	coref|coref|coref|coref	7-10[58_0]|9-37[80_56]|7-10[58_0]|9-37[80_56]
7-5	793-799	intake	abstract[54]|event[56]	new[54]|giv[56]	_	_
7-6	800-803	and	_	_	_	_
7-7	804-815	circulating	abstract[57]	new[57]	coref	9-5[71_57]
7-8	816-822	levels	abstract[57]	new[57]	_	_
7-9	823-825	of	abstract[57]	new[57]	_	_
7-10	826-830	free	abstract[57]|substance[58]	new[57]|giv[58]	ana	7-13[0_58]
7-11	831-838	choline	abstract[57]|substance[58]	new[57]|giv[58]	_	_
7-12	839-842	and	abstract[57]	new[57]	_	_
7-13	843-846	its	abstract[57]|substance|substance[60]	new[57]|giv|giv[60]	coref|coref	8-7[67_60]|8-7[67_60]
7-14	847-858	metabolites	abstract[57]|substance[60]	new[57]|giv[60]	_	_
7-15	859-861	is	_	_	_	_
7-16	862-871	concealed	_	_	_	_
7-17	872-874	by	_	_	_	_
7-18	875-886	homeostatic	abstract[61]	new[61]	_	_
7-19	887-898	regulations	abstract[61]	new[61]	_	_
7-20	899-902	and	_	_	_	_
7-21	903-908	rapid	abstract[63]	new[63]	coref	25-4[0_63]
7-22	909-915	tissue	object|abstract[63]	new|new[63]	_	_
7-23	916-922	uptake	abstract[63]	new[63]	_	_
7-24	923-924	.	_	_	_	_

#Text=Thus , concentrations of choline and its metabolites are usually within a narrow range .
8-1	925-929	Thus	_	_	_	_
8-2	930-931	,	_	_	_	_
8-3	932-946	concentrations	animal[64]	giv[64]	_	_
8-4	947-949	of	animal[64]	giv[64]	_	_
8-5	950-957	choline	animal[64]|substance	giv[64]|giv	ana	8-7
8-6	958-961	and	animal[64]	giv[64]	_	_
8-7	962-965	its	animal[64]|substance|substance[67]	giv[64]|giv|giv[67]	coref|coref	9-8|9-8
8-8	966-977	metabolites	animal[64]|substance[67]	giv[64]|giv[67]	_	_
8-9	978-981	are	_	_	_	_
8-10	982-989	usually	abstract[68]	new[68]	_	_
8-11	990-996	within	abstract[68]	new[68]	_	_
8-12	997-998	a	abstract[68]	new[68]	_	_
8-13	999-1005	narrow	abstract[68]	new[68]	_	_
8-14	1006-1011	range	abstract[68]	new[68]	_	_
8-15	1012-1013	.	_	_	_	_

#Text=In the literature , endogenous free fasting choline levels under physiological conditions range between 7 – 12 µmol/L , which could be confirmed in the present study with a mean choline concentration of 9.6 µmol/L before product intake .
9-1	1014-1016	In	_	_	_	_
9-2	1017-1020	the	abstract[69]	new[69]	_	_
9-3	1021-1031	literature	abstract[69]	new[69]	_	_
9-4	1032-1033	,	_	_	_	_
9-5	1034-1044	endogenous	abstract[71]	giv[71]	coref	11-6[87_71]
9-6	1045-1049	free	abstract[71]	giv[71]	_	_
9-7	1050-1057	fasting	abstract[71]	giv[71]	_	_
9-8	1058-1065	choline	substance|abstract[71]	giv|giv[71]	coref	9-31
9-9	1066-1072	levels	abstract[71]	giv[71]	_	_
9-10	1073-1078	under	abstract[71]	giv[71]	_	_
9-11	1079-1092	physiological	abstract[71]|abstract[72]	giv[71]|new[72]	_	_
9-12	1093-1103	conditions	abstract[71]|abstract[72]	giv[71]|new[72]	_	_
9-13	1104-1109	range	_	_	_	_
9-14	1110-1117	between	_	_	_	_
9-15	1118-1119	7	quantity[74]	new[74]	_	_
9-16	1120-1121	–	quantity[74]	new[74]	_	_
9-17	1122-1124	12	quantity|quantity[74]	new|new[74]	coref	28-36
9-18	1125-1131	µmol/L	quantity[74]	new[74]	_	_
9-19	1132-1133	,	_	_	_	_
9-20	1134-1139	which	_	_	_	_
9-21	1140-1145	could	_	_	_	_
9-22	1146-1148	be	_	_	_	_
9-23	1149-1158	confirmed	_	_	_	_
9-24	1159-1161	in	_	_	_	_
9-25	1162-1165	the	abstract[75]	giv[75]	ana	11-1[0_75]
9-26	1166-1173	present	abstract[75]	giv[75]	_	_
9-27	1174-1179	study	abstract[75]	giv[75]	_	_
9-28	1180-1184	with	abstract[75]	giv[75]	_	_
9-29	1185-1186	a	abstract[75]|quantity[77]	giv[75]|new[77]	_	_
9-30	1187-1191	mean	abstract[75]|quantity[77]	giv[75]|new[77]	_	_
9-31	1192-1199	choline	abstract[75]|substance|quantity[77]	giv[75]|giv|new[77]	coref	11-6
9-32	1200-1213	concentration	abstract[75]|quantity[77]	giv[75]|new[77]	_	_
9-33	1214-1216	of	abstract[75]|quantity[77]	giv[75]|new[77]	_	_
9-34	1217-1220	9.6	abstract[75]|quantity[77]|quantity[78]	giv[75]|new[77]|new[78]	_	_
9-35	1221-1227	µmol/L	abstract[75]|quantity[77]|quantity[78]	giv[75]|new[77]|new[78]	_	_
9-36	1228-1234	before	abstract[75]|quantity[77]	giv[75]|new[77]	_	_
9-37	1235-1242	product	abstract[75]|quantity[77]|substance|event[80]	giv[75]|new[77]|new|giv[80]	coref|coref|coref|coref	14-11[141_80]|22-21|14-11[141_80]|22-21
9-38	1243-1249	intake	abstract[75]|quantity[77]|event[80]	giv[75]|new[77]|giv[80]	_	_
9-39	1250-1251	.	_	_	_	_

#Text=Moreover , baseline values were highly comparable within all groups and within the two kinetic days .
10-1	1252-1260	Moreover	_	_	_	_
10-2	1261-1262	,	_	_	_	_
10-3	1263-1271	baseline	abstract|abstract[82]	new|new[82]	coref|coref	28-24|28-24
10-4	1272-1278	values	abstract[82]	new[82]	_	_
10-5	1279-1283	were	_	_	_	_
10-6	1284-1290	highly	_	_	_	_
10-7	1291-1301	comparable	_	_	_	_
10-8	1302-1308	within	_	_	_	_
10-9	1309-1312	all	person[83]	new[83]	coref	18-9[181_83]
10-10	1313-1319	groups	person[83]	new[83]	_	_
10-11	1320-1323	and	_	_	_	_
10-12	1324-1330	within	_	_	_	_
10-13	1331-1334	the	time[84]	new[84]	_	_
10-14	1335-1338	two	time[84]	new[84]	_	_
10-15	1339-1346	kinetic	time[84]	new[84]	_	_
10-16	1347-1351	days	time[84]	new[84]	_	_
10-17	1352-1353	.	_	_	_	_

#Text=It is well known that choline levels are influenced by nutrition , and choline sources depend on the diet , In a normal Western diet , choline can be obtained from eggs , liver , soybeans and pork , where choline is present primarily as phosphatidylcholine .
11-1	1354-1356	It	abstract	giv	coref	13-2[114_0]
11-2	1357-1359	is	_	_	_	_
11-3	1360-1364	well	_	_	_	_
11-4	1365-1370	known	_	_	_	_
11-5	1371-1375	that	_	_	_	_
11-6	1376-1383	choline	substance|abstract[87]	giv|giv[87]	coref|coref|coref|coref	11-14|12-17[106_87]|11-14|12-17[106_87]
11-7	1384-1390	levels	abstract[87]	giv[87]	_	_
11-8	1391-1394	are	_	_	_	_
11-9	1395-1405	influenced	_	_	_	_
11-10	1406-1408	by	_	_	_	_
11-11	1409-1418	nutrition	substance	new	_	_
11-12	1419-1420	,	_	_	_	_
11-13	1421-1424	and	_	_	_	_
11-14	1425-1432	choline	substance|abstract[90]	giv|new[90]	coref|coref	11-27|11-27
11-15	1433-1440	sources	abstract[90]	new[90]	_	_
11-16	1441-1447	depend	_	_	_	_
11-17	1448-1450	on	_	_	_	_
11-18	1451-1454	the	abstract[91]	new[91]	_	_
11-19	1455-1459	diet	abstract[91]	new[91]	_	_
11-20	1460-1461	,	_	_	_	_
11-21	1462-1464	In	_	_	_	_
11-22	1465-1466	a	abstract[92]	new[92]	ana	12-1[0_92]
11-23	1467-1473	normal	abstract[92]	new[92]	_	_
11-24	1474-1481	Western	abstract[92]	new[92]	_	_
11-25	1482-1486	diet	abstract[92]	new[92]	_	_
11-26	1487-1488	,	_	_	_	_
11-27	1489-1496	choline	substance	giv	coref	11-41
11-28	1497-1500	can	_	_	_	_
11-29	1501-1503	be	_	_	_	_
11-30	1504-1512	obtained	_	_	_	_
11-31	1513-1517	from	_	_	_	_
11-32	1518-1522	eggs	substance	new	coref	13-10
11-33	1523-1524	,	_	_	_	_
11-34	1525-1530	liver	object	new	_	_
11-35	1531-1532	,	_	_	_	_
11-36	1533-1541	soybeans	plant	new	_	_
11-37	1542-1545	and	_	_	_	_
11-38	1546-1550	pork	plant	new	_	_
11-39	1551-1552	,	_	_	_	_
11-40	1553-1558	where	_	_	_	_
11-41	1559-1566	choline	substance	giv	coref	12-18
11-42	1567-1569	is	_	_	_	_
11-43	1570-1577	present	_	_	_	_
11-44	1578-1587	primarily	_	_	_	_
11-45	1588-1590	as	_	_	_	_
11-46	1591-1610	phosphatidylcholine	_	_	_	_
11-47	1611-1612	.	_	_	_	_

#Text=It was shown that the consumption of a small breakfast led to 25 – 30 % higher choline levels compared to the fasting condition , and that a high choline-containing diet resulted in an up to two-fold increase in plasma choline .
12-1	1613-1615	It	abstract	giv	coref	12-28[109_0]
12-2	1616-1619	was	_	_	_	_
12-3	1620-1625	shown	_	_	_	_
12-4	1626-1630	that	_	_	_	_
12-5	1631-1634	the	event[100]	new[100]	_	_
12-6	1635-1646	consumption	event[100]	new[100]	_	_
12-7	1647-1649	of	event[100]	new[100]	_	_
12-8	1650-1651	a	event[100]|event[101]	new[100]|new[101]	_	_
12-9	1652-1657	small	event[100]|event[101]	new[100]|new[101]	_	_
12-10	1658-1667	breakfast	event[100]|event[101]	new[100]|new[101]	_	_
12-11	1668-1671	led	_	_	_	_
12-12	1672-1674	to	_	_	_	_
12-13	1675-1677	25	quantity[102]	new[102]	_	_
12-14	1678-1679	–	quantity[102]	new[102]	_	_
12-15	1680-1682	30	quantity[102]|quantity	new[102]|new	_	_
12-16	1683-1684	%	quantity	new	_	_
12-17	1685-1691	higher	abstract[106]	giv[106]	coref	17-10[171_106]
12-18	1692-1699	choline	substance|abstract[106]	giv|giv[106]	coref	12-40[113_0]
12-19	1700-1706	levels	abstract[106]	giv[106]	_	_
12-20	1707-1715	compared	_	_	_	_
12-21	1716-1718	to	_	_	_	_
12-22	1719-1722	the	abstract[108]	new[108]	_	_
12-23	1723-1730	fasting	abstract|abstract[108]	new|new[108]	_	_
12-24	1731-1740	condition	abstract[108]	new[108]	_	_
12-25	1741-1742	,	_	_	_	_
12-26	1743-1746	and	_	_	_	_
12-27	1747-1751	that	_	_	_	_
12-28	1752-1753	a	abstract[109]	giv[109]	coref	15-16[151_109]
12-29	1754-1758	high	abstract[109]	giv[109]	_	_
12-30	1759-1777	choline-containing	abstract[109]	giv[109]	_	_
12-31	1778-1782	diet	abstract[109]	giv[109]	_	_
12-32	1783-1791	resulted	_	_	_	_
12-33	1792-1794	in	_	_	_	_
12-34	1795-1797	an	abstract[110]	new[110]	_	_
12-35	1798-1800	up	abstract[110]	new[110]	_	_
12-36	1801-1803	to	abstract[110]	new[110]	_	_
12-37	1804-1812	two-fold	abstract[110]|abstract[111]	new[110]|new[111]	coref	13-53[129_111]
12-38	1813-1821	increase	abstract[110]|abstract[111]	new[110]|new[111]	_	_
12-39	1822-1824	in	abstract[110]|abstract[111]	new[110]|new[111]	_	_
12-40	1825-1831	plasma	abstract[110]|abstract[111]|abstract|substance[113]	new[110]|new[111]|giv|giv[113]	coref|coref|coref|coref	13-15[0_113]|21-11|13-15[0_113]|21-11
12-41	1832-1839	choline	abstract[110]|abstract[111]|substance[113]	new[110]|new[111]|giv[113]	_	_
12-42	1840-1841	.	_	_	_	_

#Text=In a recent study by Cho et al. , eggs were provided as a choline source , which contained comparable amounts of choline ( 479 mg ) as the herein investigated study products ( choline bitartrate : 620 mg ; Superba Boost TM : 572 mg ) . Cho et al. reported a 1.6-fold increase in free choline after consumption of the egg meal , in comparison to the fruit control meal .
13-1	1842-1844	In	_	_	_	_
13-2	1845-1846	a	abstract[114]	giv[114]	coref	13-32[0_114]
13-3	1847-1853	recent	abstract[114]	giv[114]	_	_
13-4	1854-1859	study	abstract[114]	giv[114]	_	_
13-5	1860-1862	by	abstract[114]	giv[114]	_	_
13-6	1863-1866	Cho	abstract[114]|person	giv[114]|new	coref	13-49
13-7	1867-1869	et	abstract[114]	giv[114]	_	_
13-8	1870-1873	al.	abstract[114]	giv[114]	_	_
13-9	1874-1875	,	_	_	_	_
13-10	1876-1880	eggs	object	giv	_	_
13-11	1881-1885	were	_	_	_	_
13-12	1886-1894	provided	_	_	_	_
13-13	1895-1897	as	_	_	_	_
13-14	1898-1899	a	_	_	_	_
13-15	1900-1907	choline	substance	giv	coref	13-23
13-16	1908-1914	source	_	_	_	_
13-17	1915-1916	,	_	_	_	_
13-18	1917-1922	which	_	_	_	_
13-19	1923-1932	contained	_	_	_	_
13-20	1933-1943	comparable	quantity[118]	new[118]	_	_
13-21	1944-1951	amounts	quantity[118]	new[118]	_	_
13-22	1952-1954	of	quantity[118]	new[118]	_	_
13-23	1955-1962	choline	quantity[118]|substance	new[118]|giv	coref	13-35
13-24	1963-1964	(	quantity[118]	new[118]	_	_
13-25	1965-1968	479	quantity[118]|quantity[120]	new[118]|new[120]	_	_
13-26	1969-1971	mg	quantity[118]|quantity[120]	new[118]|new[120]	_	_
13-27	1972-1973	)	quantity[118]	new[118]	_	_
13-28	1974-1976	as	quantity[118]	new[118]	_	_
13-29	1977-1980	the	quantity[118]	new[118]	_	_
13-30	1981-1987	herein	quantity[118]	new[118]	_	_
13-31	1988-2000	investigated	quantity[118]	new[118]	_	_
13-32	2001-2006	study	quantity[118]|abstract	new[118]|giv	coref	14-7[139_0]
13-33	2007-2015	products	quantity[118]	new[118]	_	_
13-34	2016-2017	(	_	_	_	_
13-35	2018-2025	choline	substance|substance[123]	giv|giv[123]	coref|coref|coref|coref	13-57[130_0]|14-16[143_123]|13-57[130_0]|14-16[143_123]
13-36	2026-2036	bitartrate	substance[123]	giv[123]	_	_
13-37	2037-2038	:	substance[123]	giv[123]	_	_
13-38	2039-2042	620	substance[123]|quantity[124]	giv[123]|new[124]	_	_
13-39	2043-2045	mg	substance[123]|quantity[124]	giv[123]|new[124]	_	_
13-40	2046-2047	;	_	_	_	_
13-41	2048-2055	Superba	substance	giv	coref	14-21
13-42	2056-2061	Boost	_	_	_	_
13-43	2062-2064	TM	object	giv	coref	14-23[146_0]
13-44	2065-2066	:	_	_	_	_
13-45	2067-2070	572	quantity[127]	new[127]	_	_
13-46	2071-2073	mg	quantity[127]	new[127]	_	_
13-47	2074-2075	)	_	_	_	_
13-48	2076-2077	.	_	_	_	_
13-49	2078-2081	Cho	person	giv	_	_
13-50	2082-2084	et	_	_	_	_
13-51	2085-2088	al.	_	_	_	_
13-52	2089-2097	reported	_	_	_	_
13-53	2098-2099	a	abstract[129]	giv[129]	coref	14-3[138_129]
13-54	2100-2108	1.6-fold	abstract[129]	giv[129]	_	_
13-55	2109-2117	increase	abstract[129]	giv[129]	_	_
13-56	2118-2120	in	abstract[129]	giv[129]	_	_
13-57	2121-2125	free	abstract[129]|substance[130]	giv[129]|giv[130]	coref	14-4[0_130]
13-58	2126-2133	choline	abstract[129]|substance[130]	giv[129]|giv[130]	_	_
13-59	2134-2139	after	abstract[129]	giv[129]	_	_
13-60	2140-2151	consumption	abstract[129]|abstract[131]	giv[129]|new[131]	_	_
13-61	2152-2154	of	abstract[129]|abstract[131]	giv[129]|new[131]	_	_
13-62	2155-2158	the	abstract[129]|abstract[131]|object[133]	giv[129]|new[131]|new[133]	coref	13-69[136_133]
13-63	2159-2162	egg	abstract[129]|abstract[131]|object|object[133]	giv[129]|new[131]|new|new[133]	_	_
13-64	2163-2167	meal	abstract[129]|abstract[131]|object[133]	giv[129]|new[131]|new[133]	_	_
13-65	2168-2169	,	_	_	_	_
13-66	2170-2172	in	_	_	_	_
13-67	2173-2183	comparison	_	_	_	_
13-68	2184-2186	to	_	_	_	_
13-69	2187-2190	the	object[136]	giv[136]	_	_
13-70	2191-2196	fruit	plant|object[136]	new|giv[136]	_	_
13-71	2197-2204	control	event|object[136]	new|giv[136]	_	_
13-72	2205-2209	meal	object[136]	giv[136]	_	_
13-73	2210-2211	.	_	_	_	_

#Text=Correspondingly , the choline increase in the current study upon supplement intake was comparable ( choline bitartrate : 1.35-fold ; Superba Boost TM : 1.48-fold ) .
14-1	2212-2227	Correspondingly	_	_	_	_
14-2	2228-2229	,	_	_	_	_
14-3	2230-2233	the	abstract[138]	giv[138]	coref	17-6[169_138]
14-4	2234-2241	choline	substance|abstract[138]	giv|giv[138]	coref	14-16
14-5	2242-2250	increase	abstract[138]	giv[138]	_	_
14-6	2251-2253	in	abstract[138]	giv[138]	_	_
14-7	2254-2257	the	abstract[138]|abstract[139]	giv[138]|giv[139]	coref	15-11[150_139]
14-8	2258-2265	current	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
14-9	2266-2271	study	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
14-10	2272-2276	upon	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
14-11	2277-2287	supplement	abstract[138]|abstract[139]|substance|event[141]	giv[138]|giv[139]|new|giv[141]	coref|coref	16-19[162_141]|16-19[162_141]
14-12	2288-2294	intake	abstract[138]|abstract[139]|event[141]	giv[138]|giv[139]|giv[141]	_	_
14-13	2295-2298	was	_	_	_	_
14-14	2299-2309	comparable	_	_	_	_
14-15	2310-2311	(	_	_	_	_
14-16	2312-2319	choline	substance|substance[143]	giv|giv[143]	coref|coref|coref|coref	15-20|22-21[223_143]|15-20|22-21[223_143]
14-17	2320-2330	bitartrate	substance[143]	giv[143]	_	_
14-18	2331-2332	:	substance[143]	giv[143]	_	_
14-19	2333-2342	1.35-fold	substance[143]	giv[143]	_	_
14-20	2343-2344	;	_	_	_	_
14-21	2345-2352	Superba	substance|abstract[145]	giv|giv[145]	coref|coref	25-20|25-20
14-22	2353-2358	Boost	abstract[145]	giv[145]	_	_
14-23	2359-2361	TM	abstract[145]|object[146]	giv[145]|giv[146]	coref	25-20[249_146]
14-24	2362-2363	:	abstract[145]|object[146]	giv[145]|giv[146]	_	_
14-25	2364-2373	1.48-fold	abstract[145]|object[146]	giv[145]|giv[146]	_	_
14-26	2374-2375	)	_	_	_	_
14-27	2376-2377	.	_	_	_	_

#Text=To control for confounding factors of food , subjects of the present study adhered to a diet low in choline three days before the study intervention and consumed standardized meals during the kinetic days .
15-1	2378-2380	To	_	_	_	_
15-2	2381-2388	control	_	_	_	_
15-3	2389-2392	for	_	_	_	_
15-4	2393-2404	confounding	_	_	_	_
15-5	2405-2412	factors	abstract[147]	new[147]	_	_
15-6	2413-2415	of	abstract[147]	new[147]	_	_
15-7	2416-2420	food	abstract[147]|substance	new[147]|new	_	_
15-8	2421-2422	,	_	_	_	_
15-9	2423-2431	subjects	abstract[149]	new[149]	coref	16-11[160_149]
15-10	2432-2434	of	abstract[149]	new[149]	_	_
15-11	2435-2438	the	abstract[149]|abstract[150]	new[149]|giv[150]	coref	15-25[0_150]
15-12	2439-2446	present	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
15-13	2447-2452	study	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
15-14	2453-2460	adhered	_	_	_	_
15-15	2461-2463	to	_	_	_	_
15-16	2464-2465	a	abstract[151]	giv[151]	_	_
15-17	2466-2470	diet	abstract[151]	giv[151]	_	_
15-18	2471-2474	low	_	_	_	_
15-19	2475-2477	in	_	_	_	_
15-20	2478-2485	choline	substance	giv	coref	16-32
15-21	2486-2491	three	time[153]	new[153]	_	_
15-22	2492-2496	days	time[153]	new[153]	_	_
15-23	2497-2503	before	_	_	_	_
15-24	2504-2507	the	event[155]	new[155]	_	_
15-25	2508-2513	study	abstract|event[155]	giv|new[155]	coref	16-6
15-26	2514-2526	intervention	event[155]	new[155]	_	_
15-27	2527-2530	and	_	_	_	_
15-28	2531-2539	consumed	_	_	_	_
15-29	2540-2552	standardized	object[156]	new[156]	_	_
15-30	2553-2558	meals	object[156]	new[156]	_	_
15-31	2559-2565	during	_	_	_	_
15-32	2566-2569	the	time[157]	new[157]	_	_
15-33	2570-2577	kinetic	time[157]	new[157]	_	_
15-34	2578-2582	days	time[157]	new[157]	_	_
15-35	2583-2584	.	_	_	_	_

#Text=In addition , a parallel study arm was included , whose subjects underwent a single kinetic dose after the intake of fish oil as a placebo control that was devoid of choline .
16-1	2585-2587	In	_	_	_	_
16-2	2588-2596	addition	_	_	_	_
16-3	2597-2598	,	_	_	_	_
16-4	2599-2600	a	abstract[159]	new[159]	_	_
16-5	2601-2609	parallel	abstract[159]	new[159]	_	_
16-6	2610-2615	study	abstract|abstract[159]	giv|new[159]	coref	18-10
16-7	2616-2619	arm	abstract[159]	new[159]	_	_
16-8	2620-2623	was	_	_	_	_
16-9	2624-2632	included	_	_	_	_
16-10	2633-2634	,	_	_	_	_
16-11	2635-2640	whose	abstract[160]	giv[160]	_	_
16-12	2641-2649	subjects	abstract[160]	giv[160]	_	_
16-13	2650-2659	underwent	_	_	_	_
16-14	2660-2661	a	abstract[161]	new[161]	_	_
16-15	2662-2668	single	abstract[161]	new[161]	_	_
16-16	2669-2676	kinetic	abstract[161]	new[161]	_	_
16-17	2677-2681	dose	abstract[161]	new[161]	_	_
16-18	2682-2687	after	_	_	_	_
16-19	2688-2691	the	event[162]	giv[162]	coref	25-24[0_162]
16-20	2692-2698	intake	event[162]	giv[162]	_	_
16-21	2699-2701	of	event[162]	giv[162]	_	_
16-22	2702-2706	fish	event[162]|animal|substance[164]	giv[162]|new|giv[164]	coref|coref	20-1[200_164]|20-1[200_164]
16-23	2707-2710	oil	event[162]|substance[164]	giv[162]|giv[164]	_	_
16-24	2711-2713	as	event[162]|substance[164]	giv[162]|giv[164]	_	_
16-25	2714-2715	a	event[162]|substance[164]	giv[162]|giv[164]	_	_
16-26	2716-2723	placebo	event[162]|substance[164]|person	giv[162]|giv[164]|new	_	_
16-27	2724-2731	control	event[162]|substance[164]	giv[162]|giv[164]	_	_
16-28	2732-2736	that	_	_	_	_
16-29	2737-2740	was	_	_	_	_
16-30	2741-2747	devoid	_	_	_	_
16-31	2748-2750	of	_	_	_	_
16-32	2751-2758	choline	substance	giv	coref	17-10
16-33	2759-2760	.	_	_	_	_

#Text=Of note , we observed a minor increase in choline levels in the placebo group after the 4 h time point ; thus , the standardized lunch served after four hours could have contributed to this elevation .
17-1	2761-2763	Of	_	_	_	_
17-2	2764-2768	note	abstract	new	_	_
17-3	2769-2770	,	_	_	_	_
17-4	2771-2773	we	person	acc	ana	19-10
17-5	2774-2782	observed	_	_	_	_
17-6	2783-2784	a	abstract[169]	giv[169]	coref	22-7[217_169]
17-7	2785-2790	minor	abstract[169]	giv[169]	_	_
17-8	2791-2799	increase	abstract[169]	giv[169]	_	_
17-9	2800-2802	in	abstract[169]	giv[169]	_	_
17-10	2803-2810	choline	abstract[169]|substance|abstract[171]	giv[169]|giv|giv[171]	coref|coref|coref|coref	18-13|19-20[189_171]|18-13|19-20[189_171]
17-11	2811-2817	levels	abstract[169]|abstract[171]	giv[169]|giv[171]	_	_
17-12	2818-2820	in	abstract[169]|abstract[171]	giv[169]|giv[171]	_	_
17-13	2821-2824	the	abstract[169]|abstract[171]|person[172]	giv[169]|giv[171]|new[172]	_	_
17-14	2825-2832	placebo	abstract[169]|abstract[171]|person[172]	giv[169]|giv[171]|new[172]	_	_
17-15	2833-2838	group	abstract[169]|abstract[171]|person[172]	giv[169]|giv[171]|new[172]	_	_
17-16	2839-2844	after	abstract[169]|abstract[171]|person[172]	giv[169]|giv[171]|new[172]	_	_
17-17	2845-2848	the	abstract[169]|abstract[171]|person[172]|time[175]	giv[169]|giv[171]|new[172]|new[175]	_	_
17-18	2849-2850	4	abstract[169]|abstract[171]|person[172]|time[175]	giv[169]|giv[171]|new[172]|new[175]	_	_
17-19	2851-2852	h	abstract[169]|abstract[171]|person[172]|quantity|time[175]	giv[169]|giv[171]|new[172]|new|new[175]	_	_
17-20	2853-2857	time	abstract[169]|abstract[171]|person[172]|event|time[175]	giv[169]|giv[171]|new[172]|new|new[175]	_	_
17-21	2858-2863	point	abstract[169]|abstract[171]|person[172]|time[175]	giv[169]|giv[171]|new[172]|new[175]	_	_
17-22	2864-2865	;	_	_	_	_
17-23	2866-2870	thus	_	_	_	_
17-24	2871-2872	,	_	_	_	_
17-25	2873-2876	the	event[176]	new[176]	_	_
17-26	2877-2889	standardized	event[176]	new[176]	_	_
17-27	2890-2895	lunch	event[176]	new[176]	_	_
17-28	2896-2902	served	_	_	_	_
17-29	2903-2908	after	_	_	_	_
17-30	2909-2913	four	time[177]	new[177]	_	_
17-31	2914-2919	hours	time[177]	new[177]	_	_
17-32	2920-2925	could	_	_	_	_
17-33	2926-2930	have	_	_	_	_
17-34	2931-2942	contributed	_	_	_	_
17-35	2943-2945	to	_	_	_	_
17-36	2946-2950	this	abstract[178]	new[178]	coref	19-32[192_178]
17-37	2951-2960	elevation	abstract[178]	new[178]	_	_
17-38	2961-2962	.	_	_	_	_

#Text=However , no such effect was seen in the study groups receiving choline supplements .
18-1	2963-2970	However	_	_	_	_
18-2	2971-2972	,	_	_	_	_
18-3	2973-2975	no	abstract[179]	new[179]	_	_
18-4	2976-2980	such	abstract[179]	new[179]	_	_
18-5	2981-2987	effect	abstract[179]	new[179]	_	_
18-6	2988-2991	was	_	_	_	_
18-7	2992-2996	seen	_	_	_	_
18-8	2997-2999	in	_	_	_	_
18-9	3000-3003	the	person[181]	giv[181]	_	_
18-10	3004-3009	study	abstract|person[181]	giv|giv[181]	coref	21-2[207_0]
18-11	3010-3016	groups	person[181]	giv[181]	_	_
18-12	3017-3026	receiving	_	_	_	_
18-13	3027-3034	choline	substance|substance[183]	giv|new[183]	coref|coref	19-20|19-20
18-14	3035-3046	supplements	substance[183]	new[183]	_	_
18-15	3047-3048	.	_	_	_	_

#Text=In addition , by implementing the control group , we were able to exclude possible circadian rhythm-dependent variations in choline levels , in contrast to Park et al. , who observed a slight elevation of free choline levels in the afternoon during a 12 h-lasting observation of endogenous choline levels .
19-1	3049-3051	In	_	_	_	_
19-2	3052-3060	addition	_	_	_	_
19-3	3061-3062	,	_	_	_	_
19-4	3063-3065	by	_	_	_	_
19-5	3066-3078	implementing	_	_	_	_
19-6	3079-3082	the	person[184]	new[184]	_	_
19-7	3083-3090	control	person[184]	new[184]	_	_
19-8	3091-3096	group	person[184]	new[184]	_	_
19-9	3097-3098	,	_	_	_	_
19-10	3099-3101	we	person	giv	ana	22-5
19-11	3102-3106	were	_	_	_	_
19-12	3107-3111	able	_	_	_	_
19-13	3112-3114	to	_	_	_	_
19-14	3115-3122	exclude	_	_	_	_
19-15	3123-3131	possible	person[186]	new[186]	_	_
19-16	3132-3141	circadian	person[186]	new[186]	_	_
19-17	3142-3158	rhythm-dependent	abstract[187]	new[187]	_	_
19-18	3159-3169	variations	abstract[187]	new[187]	_	_
19-19	3170-3172	in	abstract[187]	new[187]	_	_
19-20	3173-3180	choline	abstract[187]|substance|abstract[189]	new[187]|giv|giv[189]	coref|coref|coref|coref	19-37|19-36[194_189]|19-37|19-36[194_189]
19-21	3181-3187	levels	abstract[187]|abstract[189]	new[187]|giv[189]	_	_
19-22	3188-3189	,	_	_	_	_
19-23	3190-3192	in	_	_	_	_
19-24	3193-3201	contrast	abstract[190]	new[190]	_	_
19-25	3202-3204	to	abstract[190]	new[190]	_	_
19-26	3205-3209	Park	abstract[190]|person	new[190]|new	_	_
19-27	3210-3212	et	abstract[190]	new[190]	_	_
19-28	3213-3216	al.	abstract[190]	new[190]	_	_
19-29	3217-3218	,	_	_	_	_
19-30	3219-3222	who	_	_	_	_
19-31	3223-3231	observed	_	_	_	_
19-32	3232-3233	a	abstract[192]	giv[192]	_	_
19-33	3234-3240	slight	abstract[192]	giv[192]	_	_
19-34	3241-3250	elevation	abstract[192]	giv[192]	_	_
19-35	3251-3253	of	abstract[192]	giv[192]	_	_
19-36	3254-3258	free	abstract[192]|abstract[194]	giv[192]|giv[194]	coref	19-48[198_194]
19-37	3259-3266	choline	abstract[192]|substance|abstract[194]	giv[192]|giv|giv[194]	coref	19-49
19-38	3267-3273	levels	abstract[192]|abstract[194]	giv[192]|giv[194]	_	_
19-39	3274-3276	in	abstract[192]|abstract[194]	giv[192]|giv[194]	_	_
19-40	3277-3280	the	abstract[192]|abstract[194]|time[195]	giv[192]|giv[194]|new[195]	_	_
19-41	3281-3290	afternoon	abstract[192]|abstract[194]|time[195]	giv[192]|giv[194]|new[195]	_	_
19-42	3291-3297	during	_	_	_	_
19-43	3298-3299	a	event[196]	new[196]	_	_
19-44	3300-3302	12	event[196]	new[196]	_	_
19-45	3303-3312	h-lasting	event[196]	new[196]	_	_
19-46	3313-3324	observation	event[196]	new[196]	_	_
19-47	3325-3327	of	event[196]	new[196]	_	_
19-48	3328-3338	endogenous	event[196]|abstract[198]	new[196]|giv[198]	coref	21-11[211_198]
19-49	3339-3346	choline	event[196]|substance|abstract[198]	new[196]|giv|giv[198]	coref	21-12
19-50	3347-3353	levels	event[196]|abstract[198]	new[196]|giv[198]	_	_
19-51	3354-3355	.	_	_	_	_

#Text=Krill oil is increasingly recognized as a useful source of phosphatidylcholine , in addition to its acknowledged role in providing the omega-3 fatty acids EPA and DHA .
20-1	3356-3361	Krill	abstract|substance[200]	giv|giv[200]	_	_
20-2	3362-3365	oil	substance[200]	giv[200]	_	_
20-3	3366-3368	is	_	_	_	_
20-4	3369-3381	increasingly	_	_	_	_
20-5	3382-3392	recognized	_	_	_	_
20-6	3393-3395	as	_	_	_	_
20-7	3396-3397	a	_	_	_	_
20-8	3398-3404	useful	_	_	_	_
20-9	3405-3411	source	_	_	_	_
20-10	3412-3414	of	_	_	_	_
20-11	3415-3434	phosphatidylcholine	substance	new	ana	20-16
20-12	3435-3436	,	_	_	_	_
20-13	3437-3439	in	_	_	_	_
20-14	3440-3448	addition	_	_	_	_
20-15	3449-3451	to	_	_	_	_
20-16	3452-3455	its	substance|abstract[203]	giv|new[203]	coref|coref	21-6|21-6
20-17	3456-3468	acknowledged	abstract[203]	new[203]	_	_
20-18	3469-3473	role	abstract[203]	new[203]	_	_
20-19	3474-3476	in	_	_	_	_
20-20	3477-3486	providing	_	_	_	_
20-21	3487-3490	the	abstract[204]	new[204]	_	_
20-22	3491-3498	omega-3	abstract[204]	new[204]	_	_
20-23	3499-3504	fatty	abstract[204]	new[204]	_	_
20-24	3505-3510	acids	abstract[204]	new[204]	_	_
20-25	3511-3514	EPA	abstract[204]|organization	new[204]|new	_	_
20-26	3515-3518	and	abstract[204]	new[204]	_	_
20-27	3519-3522	DHA	abstract[204]|abstract	new[204]|new	_	_
20-28	3523-3524	.	_	_	_	_

#Text=In a former study , phosphatidylcholine was shown to raise plasma choline levels more efficiently compared to ingestion of free choline as choline chloride .
21-1	3525-3527	In	_	_	_	_
21-2	3528-3529	a	abstract[207]	giv[207]	coref	22-2[215_207]
21-3	3530-3536	former	abstract[207]	giv[207]	_	_
21-4	3537-3542	study	abstract[207]	giv[207]	_	_
21-5	3543-3544	,	_	_	_	_
21-6	3545-3564	phosphatidylcholine	substance	giv	coref	22-16[220_0]
21-7	3565-3568	was	_	_	_	_
21-8	3569-3574	shown	_	_	_	_
21-9	3575-3577	to	_	_	_	_
21-10	3578-3583	raise	_	_	_	_
21-11	3584-3590	plasma	abstract|abstract[211]	giv|giv[211]	coref|coref	28-11[284_211]|28-11[284_211]
21-12	3591-3598	choline	substance|abstract[211]	giv|giv[211]	coref	21-20[213_0]
21-13	3599-3605	levels	abstract[211]	giv[211]	_	_
21-14	3606-3610	more	_	_	_	_
21-15	3611-3622	efficiently	_	_	_	_
21-16	3623-3631	compared	_	_	_	_
21-17	3632-3634	to	_	_	_	_
21-18	3635-3644	ingestion	event[212]	new[212]	_	_
21-19	3645-3647	of	event[212]	new[212]	_	_
21-20	3648-3652	free	event[212]|substance[213]	new[212]|giv[213]	coref	21-23[0_213]
21-21	3653-3660	choline	event[212]|substance[213]	new[212]|giv[213]	_	_
21-22	3661-3663	as	event[212]	new[212]	_	_
21-23	3664-3671	choline	event[212]|substance	new[212]|giv	coref	22-11
21-24	3672-3680	chloride	event[212]	new[212]	_	_
21-25	3681-3682	.	_	_	_	_

#Text=In the current study we observed a significant increase of choline after single doses of both phosphatidylcholine and the reference product choline bitartrate ; however , phosphatidylcholine was not more efficient , since there were no significant differences in the pharmacokinetic endpoints AUC and Cmax .
22-1	3683-3685	In	_	_	_	_
22-2	3686-3689	the	abstract[215]	giv[215]	coref	23-5[230_215]
22-3	3690-3697	current	abstract[215]	giv[215]	_	_
22-4	3698-3703	study	abstract[215]	giv[215]	_	_
22-5	3704-3706	we	person	giv	ana	24-7
22-6	3707-3715	observed	_	_	_	_
22-7	3716-3717	a	abstract[217]	giv[217]	coref	25-14[246_217]
22-8	3718-3729	significant	abstract[217]	giv[217]	_	_
22-9	3730-3738	increase	abstract[217]	giv[217]	_	_
22-10	3739-3741	of	abstract[217]	giv[217]	_	_
22-11	3742-3749	choline	abstract[217]|substance	giv[217]|giv	coref	22-22
22-12	3750-3755	after	abstract[217]	giv[217]	_	_
22-13	3756-3762	single	abstract[217]|abstract[219]	giv[217]|new[219]	_	_
22-14	3763-3768	doses	abstract[217]|abstract[219]	giv[217]|new[219]	_	_
22-15	3769-3771	of	abstract[217]|abstract[219]	giv[217]|new[219]	_	_
22-16	3772-3776	both	abstract[217]|abstract[219]|substance[220]	giv[217]|new[219]|giv[220]	coref	22-27[0_220]
22-17	3777-3796	phosphatidylcholine	abstract[217]|abstract[219]|substance[220]	giv[217]|new[219]|giv[220]	_	_
22-18	3797-3800	and	abstract[217]|abstract[219]	giv[217]|new[219]	_	_
22-19	3801-3804	the	abstract[217]|abstract[219]	giv[217]|new[219]	_	_
22-20	3805-3814	reference	abstract[217]|abstract[219]	giv[217]|new[219]	_	_
22-21	3815-3822	product	abstract[217]|abstract[219]|substance|substance[223]	giv[217]|new[219]|giv|giv[223]	coref|coref	24-10[237_223]|24-10[237_223]
22-22	3823-3830	choline	abstract[217]|abstract[219]|substance|substance[223]	giv[217]|new[219]|giv|giv[223]	coref	23-20
22-23	3831-3841	bitartrate	abstract[217]|abstract[219]|substance[223]	giv[217]|new[219]|giv[223]	_	_
22-24	3842-3843	;	_	_	_	_
22-25	3844-3851	however	_	_	_	_
22-26	3852-3853	,	_	_	_	_
22-27	3854-3873	phosphatidylcholine	substance	giv	coref	25-18
22-28	3874-3877	was	_	_	_	_
22-29	3878-3881	not	_	_	_	_
22-30	3882-3886	more	_	_	_	_
22-31	3887-3896	efficient	_	_	_	_
22-32	3897-3898	,	_	_	_	_
22-33	3899-3904	since	_	_	_	_
22-34	3905-3910	there	_	_	_	_
22-35	3911-3915	were	_	_	_	_
22-36	3916-3918	no	abstract[225]	new[225]	coref	23-12[231_225]
22-37	3919-3930	significant	abstract[225]	new[225]	_	_
22-38	3931-3942	differences	abstract[225]	new[225]	_	_
22-39	3943-3945	in	abstract[225]	new[225]	_	_
22-40	3946-3949	the	abstract[225]|abstract[227]	new[225]|new[227]	_	_
22-41	3950-3965	pharmacokinetic	abstract[225]|abstract|abstract[227]	new[225]|giv|new[227]	_	_
22-42	3966-3975	endpoints	abstract[225]|abstract[227]	new[225]|new[227]	_	_
22-43	3976-3979	AUC	_	_	_	_
22-44	3980-3983	and	_	_	_	_
22-45	3984-3988	Cmax	abstract	new	_	_
22-46	3989-3990	.	_	_	_	_

#Text=This discrepancy compared to the former study could be due to possible differences in the bioavailability of the chosen choline salts .
23-1	3991-3995	This	abstract[229]	new[229]	_	_
23-2	3996-4007	discrepancy	abstract[229]	new[229]	_	_
23-3	4008-4016	compared	_	_	_	_
23-4	4017-4019	to	_	_	_	_
23-5	4020-4023	the	abstract[230]	giv[230]	coref	25-10[245_230]
23-6	4024-4030	former	abstract[230]	giv[230]	_	_
23-7	4031-4036	study	abstract[230]	giv[230]	_	_
23-8	4037-4042	could	_	_	_	_
23-9	4043-4045	be	_	_	_	_
23-10	4046-4049	due	_	_	_	_
23-11	4050-4052	to	_	_	_	_
23-12	4053-4061	possible	abstract[231]	giv[231]	coref	26-12[257_231]
23-13	4062-4073	differences	abstract[231]	giv[231]	_	_
23-14	4074-4076	in	abstract[231]	giv[231]	_	_
23-15	4077-4080	the	abstract[231]|substance[232]	giv[231]|new[232]	coref	24-13[240_232]
23-16	4081-4096	bioavailability	abstract[231]|substance[232]	giv[231]|new[232]	_	_
23-17	4097-4099	of	abstract[231]|substance[232]	giv[231]|new[232]	_	_
23-18	4100-4103	the	abstract[231]|substance[232]|substance[234]	giv[231]|new[232]|new[234]	_	_
23-19	4104-4110	chosen	abstract[231]|substance[232]|substance[234]	giv[231]|new[232]|new[234]	_	_
23-20	4111-4118	choline	abstract[231]|substance[232]|substance|substance[234]	giv[231]|new[232]|giv|new[234]	coref	24-13
23-21	4119-4124	salts	abstract[231]|substance[232]|substance[234]	giv[231]|new[232]|new[234]	_	_
23-22	4125-4126	.	_	_	_	_

#Text=However , to the best of our knowledge , choline bitartrate and choline chloride bioavailability has not been directly compared to date .
24-1	4127-4134	However	_	_	_	_
24-2	4135-4136	,	_	_	_	_
24-3	4137-4139	to	_	_	_	_
24-4	4140-4143	the	_	_	_	_
24-5	4144-4148	best	_	_	_	_
24-6	4149-4151	of	_	_	_	_
24-7	4152-4155	our	person|abstract[236]	giv|new[236]	ana|ana	28-1|28-1
24-8	4156-4165	knowledge	abstract[236]	new[236]	_	_
24-9	4166-4167	,	_	_	_	_
24-10	4168-4175	choline	substance[237]	giv[237]	coref	25-27[252_237]
24-11	4176-4186	bitartrate	substance[237]	giv[237]	_	_
24-12	4187-4190	and	_	_	_	_
24-13	4191-4198	choline	substance|substance[240]	giv|giv[240]	coref|coref	25-7[244_0]|25-7[244_0]
24-14	4199-4207	chloride	abstract|substance[240]	new|giv[240]	coref	28-14[286_0]
24-15	4208-4223	bioavailability	substance[240]	giv[240]	_	_
24-16	4224-4227	has	_	_	_	_
24-17	4228-4231	not	_	_	_	_
24-18	4232-4236	been	_	_	_	_
24-19	4237-4245	directly	_	_	_	_
24-20	4246-4254	compared	_	_	_	_
24-21	4255-4257	to	_	_	_	_
24-22	4258-4262	date	time	new	_	_
24-23	4263-4264	.	_	_	_	_

#Text=Still , the uptake profile of free choline in the current study indicated a slower increase upon phosphatidylcholine ( Superba Boost TM ) intake compared to choline bitartrate .
25-1	4265-4270	Still	_	_	_	_
25-2	4271-4272	,	_	_	_	_
25-3	4273-4276	the	abstract[243]	new[243]	_	_
25-4	4277-4283	uptake	abstract|abstract[243]	giv|new[243]	_	_
25-5	4284-4291	profile	abstract[243]	new[243]	_	_
25-6	4292-4294	of	abstract[243]	new[243]	_	_
25-7	4295-4299	free	abstract[243]|substance[244]	new[243]|giv[244]	coref	25-27[0_244]
25-8	4300-4307	choline	abstract[243]|substance[244]	new[243]|giv[244]	_	_
25-9	4308-4310	in	abstract[243]|substance[244]	new[243]|giv[244]	_	_
25-10	4311-4314	the	abstract[243]|substance[244]|abstract[245]	new[243]|giv[244]|giv[245]	coref	26-7[0_245]
25-11	4315-4322	current	abstract[243]|substance[244]|abstract[245]	new[243]|giv[244]|giv[245]	_	_
25-12	4323-4328	study	abstract[243]|substance[244]|abstract[245]	new[243]|giv[244]|giv[245]	_	_
25-13	4329-4338	indicated	_	_	_	_
25-14	4339-4340	a	abstract[246]	giv[246]	_	_
25-15	4341-4347	slower	abstract[246]	giv[246]	_	_
25-16	4348-4356	increase	abstract[246]	giv[246]	_	_
25-17	4357-4361	upon	abstract[246]	giv[246]	_	_
25-18	4362-4381	phosphatidylcholine	abstract[246]|substance	giv[246]|giv	coref	27-1[263_0]
25-19	4382-4383	(	_	_	_	_
25-20	4384-4391	Superba	substance|abstract[249]	giv|giv[249]	_	_
25-21	4392-4397	Boost	abstract[249]	giv[249]	_	_
25-22	4398-4400	TM	abstract[249]	giv[249]	_	_
25-23	4401-4402	)	_	_	_	_
25-24	4403-4409	intake	event	giv	coref	28-25[290_0]
25-25	4410-4418	compared	_	_	_	_
25-26	4419-4421	to	_	_	_	_
25-27	4422-4429	choline	substance|substance[252]	giv|giv[252]	coref|coref|coref|coref	26-17|27-41[275_252]|26-17|27-41[275_252]
25-28	4430-4440	bitartrate	substance[252]	giv[252]	_	_
25-29	4441-4442	.	_	_	_	_

#Text=This difference in Tmax between the study products could result from the structural differences between the choline forms and from the associated differences in absorption and metabolism .
26-1	4443-4447	This	abstract[253]	new[253]	_	_
26-2	4448-4458	difference	abstract[253]	new[253]	_	_
26-3	4459-4461	in	abstract[253]	new[253]	_	_
26-4	4462-4466	Tmax	abstract[253]|abstract[254]	new[253]|new[254]	_	_
26-5	4467-4474	between	abstract[253]|abstract[254]	new[253]|new[254]	_	_
26-6	4475-4478	the	abstract[253]|abstract[254]|object[256]	new[253]|new[254]|new[256]	_	_
26-7	4479-4484	study	abstract[253]|abstract[254]|abstract|object[256]	new[253]|new[254]|giv|new[256]	_	_
26-8	4485-4493	products	abstract[253]|abstract[254]|object[256]	new[253]|new[254]|new[256]	_	_
26-9	4494-4499	could	_	_	_	_
26-10	4500-4506	result	_	_	_	_
26-11	4507-4511	from	_	_	_	_
26-12	4512-4515	the	abstract[257]	giv[257]	coref	26-21[260_257]
26-13	4516-4526	structural	abstract[257]	giv[257]	_	_
26-14	4527-4538	differences	abstract[257]	giv[257]	_	_
26-15	4539-4546	between	abstract[257]	giv[257]	_	_
26-16	4547-4550	the	abstract[257]|substance[259]	giv[257]|new[259]	_	_
26-17	4551-4558	choline	abstract[257]|substance|substance[259]	giv[257]|giv|new[259]	coref	27-18[267_0]
26-18	4559-4564	forms	abstract[257]|substance[259]	giv[257]|new[259]	_	_
26-19	4565-4568	and	_	_	_	_
26-20	4569-4573	from	_	_	_	_
26-21	4574-4577	the	abstract[260]	giv[260]	_	_
26-22	4578-4588	associated	abstract[260]	giv[260]	_	_
26-23	4589-4600	differences	abstract[260]	giv[260]	_	_
26-24	4601-4603	in	abstract[260]	giv[260]	_	_
26-25	4604-4614	absorption	abstract[260]|abstract	giv[260]|new	_	_
26-26	4615-4618	and	abstract[260]	giv[260]	_	_
26-27	4619-4629	metabolism	abstract[260]|abstract	giv[260]|new	_	_
26-28	4630-4631	.	_	_	_	_

#Text=Phosphatidylcholine and/or its isoforms may be absorbed intact and can also be hydrolyzed into phosphatidic acid and free choline by phospholipase D. Due to this conversion step , it supposedly takes longer to obtain free choline from phosphatidylcholine compared to choline bitartrate , where free choline from the salt structure is more rapidly available .
27-1	4632-4651	Phosphatidylcholine	substance[263]	giv[263]	ana	27-29[0_263]
27-2	4652-4658	and/or	substance[263]	giv[263]	_	_
27-3	4659-4662	its	substance[263]|substance[264]	giv[263]|new[264]	_	_
27-4	4663-4671	isoforms	substance[263]|substance[264]	giv[263]|new[264]	_	_
27-5	4672-4675	may	_	_	_	_
27-6	4676-4678	be	_	_	_	_
27-7	4679-4687	absorbed	_	_	_	_
27-8	4688-4694	intact	_	_	_	_
27-9	4695-4698	and	_	_	_	_
27-10	4699-4702	can	_	_	_	_
27-11	4703-4707	also	_	_	_	_
27-12	4708-4710	be	_	_	_	_
27-13	4711-4721	hydrolyzed	_	_	_	_
27-14	4722-4726	into	_	_	_	_
27-15	4727-4739	phosphatidic	person|substance[266]	new|new[266]	_	_
27-16	4740-4744	acid	substance[266]	new[266]	_	_
27-17	4745-4748	and	_	_	_	_
27-18	4749-4753	free	substance[267]	giv[267]	coref	27-35[272_267]
27-19	4754-4761	choline	substance[267]	giv[267]	_	_
27-20	4762-4764	by	_	_	_	_
27-21	4765-4778	phospholipase	abstract[268]	new[268]	_	_
27-22	4779-4781	D.	abstract[268]	new[268]	_	_
27-23	4782-4785	Due	abstract[268]	new[268]	_	_
27-24	4786-4788	to	_	_	_	_
27-25	4789-4793	this	event[270]	new[270]	_	_
27-26	4794-4804	conversion	abstract|event[270]	new|new[270]	_	_
27-27	4805-4809	step	event[270]	new[270]	_	_
27-28	4810-4811	,	_	_	_	_
27-29	4812-4814	it	substance	giv	coref	27-38
27-30	4815-4825	supposedly	_	_	_	_
27-31	4826-4831	takes	_	_	_	_
27-32	4832-4838	longer	_	_	_	_
27-33	4839-4841	to	_	_	_	_
27-34	4842-4848	obtain	_	_	_	_
27-35	4849-4853	free	substance[272]	giv[272]	coref	27-41[0_272]
27-36	4854-4861	choline	substance[272]	giv[272]	_	_
27-37	4862-4866	from	_	_	_	_
27-38	4867-4886	phosphatidylcholine	substance	giv	coref	28-28
27-39	4887-4895	compared	_	_	_	_
27-40	4896-4898	to	_	_	_	_
27-41	4899-4906	choline	substance|substance[275]	giv|giv[275]	coref|coref	27-45[276_0]|27-45[276_0]
27-42	4907-4917	bitartrate	substance[275]	giv[275]	_	_
27-43	4918-4919	,	_	_	_	_
27-44	4920-4925	where	_	_	_	_
27-45	4926-4930	free	substance[276]	giv[276]	coref	28-11[0_276]
27-46	4931-4938	choline	substance[276]	giv[276]	_	_
27-47	4939-4943	from	substance[276]	giv[276]	_	_
27-48	4944-4947	the	substance[276]|abstract[278]	giv[276]|new[278]	_	_
27-49	4948-4952	salt	substance[276]|substance|abstract[278]	giv[276]|new|new[278]	_	_
27-50	4953-4962	structure	substance[276]|abstract[278]	giv[276]|new[278]	_	_
27-51	4963-4965	is	_	_	_	_
27-52	4966-4970	more	_	_	_	_
27-53	4971-4978	rapidly	_	_	_	_
27-54	4979-4988	available	_	_	_	_
27-55	4989-4990	.	_	_	_	_

#Text=Our findings are in agreement with former findings showing that choline levels after choline chloride reached peak levels earlier and were reduced to baseline earlier than after phosphatidylcholine intake , where levels remained elevated for 12 h.
28-1	4991-4994	Our	person|abstract[280]	giv|new[280]	_	_
28-2	4995-5003	findings	abstract[280]	new[280]	_	_
28-3	5004-5007	are	_	_	_	_
28-4	5008-5010	in	_	_	_	_
28-5	5011-5020	agreement	abstract[281]	new[281]	_	_
28-6	5021-5025	with	abstract[281]	new[281]	_	_
28-7	5026-5032	former	abstract[281]|abstract[282]	new[281]|new[282]	_	_
28-8	5033-5041	findings	abstract[281]|abstract[282]	new[281]|new[282]	_	_
28-9	5042-5049	showing	_	_	_	_
28-10	5050-5054	that	_	_	_	_
28-11	5055-5062	choline	substance|abstract[284]	giv|giv[284]	coref|coref|coref|coref	28-14|28-17[287_284]|28-14|28-17[287_284]
28-12	5063-5069	levels	abstract[284]	giv[284]	_	_
28-13	5070-5075	after	_	_	_	_
28-14	5076-5083	choline	substance|abstract[286]	giv|giv[286]	_	_
28-15	5084-5092	chloride	abstract[286]	giv[286]	_	_
28-16	5093-5100	reached	_	_	_	_
28-17	5101-5105	peak	abstract[287]	giv[287]	coref	28-32[0_287]
28-18	5106-5112	levels	abstract[287]	giv[287]	_	_
28-19	5113-5120	earlier	_	_	_	_
28-20	5121-5124	and	_	_	_	_
28-21	5125-5129	were	_	_	_	_
28-22	5130-5137	reduced	_	_	_	_
28-23	5138-5140	to	_	_	_	_
28-24	5141-5149	baseline	abstract	giv	_	_
28-25	5150-5157	earlier	event[290]	giv[290]	_	_
28-26	5158-5162	than	event[290]	giv[290]	_	_
28-27	5163-5168	after	event[290]	giv[290]	_	_
28-28	5169-5188	phosphatidylcholine	substance|event[290]	giv|giv[290]	_	_
28-29	5189-5195	intake	event[290]	giv[290]	_	_
28-30	5196-5197	,	_	_	_	_
28-31	5198-5203	where	_	_	_	_
28-32	5204-5210	levels	abstract	giv	_	_
28-33	5211-5219	remained	_	_	_	_
28-34	5220-5228	elevated	_	_	_	_
28-35	5229-5232	for	_	_	_	_
28-36	5233-5235	12	quantity	giv	_	_
28-37	5236-5238	h.	quantity	new	_	_
